NATALIA LAPTEVA to Male
This is a "connection" page, showing publications NATALIA LAPTEVA has written about Male.
Connection Strength
0.062
-
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother. 2015 Jan; 38(1):24-36.
Score: 0.020
-
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature. 2025 Jan; 637(8047):940-946.
Score: 0.010
-
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors. J Clin Oncol. 2024 Aug 10; 42(23):2769-2779.
Score: 0.009
-
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial. Nat Cancer. 2024 06; 5(6):880-894.
Score: 0.009
-
Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia. Cytotherapy. 2017 10; 19(10):1225-1232.
Score: 0.006
-
Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Ther. 2011 Oct; 21(5):299-314.
Score: 0.004
-
The phosphatase SRC homology region 2 domain-containing phosphatase-1 is an intrinsic central regulator of dendritic cell function. J Immunol. 2011 Apr 01; 186(7):3934-45.
Score: 0.004